This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NexMed Announces Expansion Of Senior Business Development Team

NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT ® technology, today announced the expansion of its senior business development team within NexMed (U.S.A.), with the appointments of Linda Smibert as Vice President of Business Development and Mark S. Wilson as Vice-President of Technology Development. Both executives will report to Vivian Liu, the Company’s Executive Vice-President.

In her new position, effective May 26, 2010, Ms. Smibert will spearhead the out-licensing of NexMed’s pre-clinical and clinical product pipeline. Prior to joining the Company, Ms. Smibert served for eight years as Senior Director and Director of Business Development at Santarus, Inc., where she led licensing deals with GlaxoSmithKline and Norgine, a co-promotion arrangement with Otsuka America, and contributed to alliances with Schering-Plough and others. Ms. Smibert has over 20 years of experience in the pharmaceutical industry, and, in addition to her tenure at Santarus, has held a variety of business development and strategic planning management functions at Bristol-Myers Squibb in the U.S. and in Canada, as well as with Zeneca in Canada and the U.K. Ms. Smibert earned her B.A. from the University of British Columbia and an MBA from the University of Toronto.

In his new position, effective May 24, 2010, Mr. Wilson is responsible for the out-licensing of the NexACT technology. Mr. Wilson brings to NexMed over 20 years of experience in the biopharmaceutical, diagnostic and medical device industries. Prior to joining NexMed, he was Entrepreneur-in-Residence at CONNECT in San Diego, where he provided business start-up strategy, development and sourcing consulting services to local companies. Prior to that, he served for five years as Vice President of Business Development at Halozyme Therapeutics, where, among others, he was responsible for initiating the company’s $612 million alliance with F. Hoffmann-La Roche and for various alliances with Baxter Healthcare. Mr. Wilson earned a B.S. in Mechanical Engineering from the University of California, Berkeley, and an MBA from the University of California, Los Angeles.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs